Familial ATTR-CM (ATTRm-CM, or FAC)

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BridgeBio Pharma
BridgeBio PharmaCA - Palo Alto
1 program
1
AG10Phase 21 trial
Active Trials
NCT03458130Completed49Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BridgeBio PharmaAG10

Clinical Trials (1)

Total enrollment: 49 patients across 1 trials

NCT03458130BridgeBio PharmaAG10

Study of AG10 in Amyloid Cardiomyopathy

Start: Apr 2018Est. completion: Oct 201849 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space